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Abstract: Two bacterial isolates from the Barents Sea, both belonging to the genus Algibacter, were
found to yield extracts with anti-bacterial bioactivity. Mass spectrometry guided dereplication
and purification of the active extracts lead to the isolation of the same active principle in both
extracts. The structure of the bioactive compound was identified via mass spectrometry and nuclear
resonance spectroscopy and it turned out to be the known lipopeptide Lipid 430. We discovered and
determined its previously unknown anti-bacterial activity against Streptococcus agalactiae and revealed
a cytotoxic effect against the A2058 human melanoma cell line at significantly lower concentrations
compared to its anti-bacterial concentration. Flow cytometry and microscopy investigations of the
cytotoxicity against the melanoma cell line indicated that Lipid 430 did not cause immediate cell lysis.
The experiments with melanoma cells suggest that the compound functions trough more complex
pathways than acting as a simple detergent.
Keywords: flavolipin; marine bacteria; natural products; lipopeptides; algibacter
1. Introduction
The genus Bacteriocides represents the second most abundant bacterial phylum within the
marine heterotrophic picoplankton [1]. Bacteriocides, to which Flavobacteria belong, have the enzymes
required to degrade proteins and carbohydrates [2], and play an important role in the degradation
of organic matter within the marine environment. Remarkably, the observation of the abundance
of marine Flavobacteria and the hypothesis that their presence is linked to their ability to degrade
algal polymers dates back to 1946 [3]. Within the Flavobacteriaceae family, the genus Algibacter
was erected in 2004. It represents a taxon of rod-shaped, facultative anaerobic, Gram negative
bacteria, unable to form endospores [4]. Its first representative, Algibacter lectus, was isolated from
green algae and described in 2004 by Nedashkovskaya et al. [4]. Further representatives have been
isolated from seawater [5,6], invertebrates [7] and from algae or in close proximity to them [4,8–10].
Algibacter alginolytica was isolated from a brown seaweed (Laminaria japonica). Sequencing and
genomic analysis revealed that it has the highest proportion of carbohydrate-active enzymes (~7.5%)
among the Flavobacteria. The bacterium was shown to hydrolyze Tween 20, Tween 40, Tween 60,
Tween 80, galantine, alginate and starch, which indicates the ecological significance of Algibacter in
breaking down algal biopolymers [10]. As part of this work, a lipopeptide known as Lipid 430 (1,
Figure 1) was isolated. A novel serine dipeptide lipid, Lipid 654 (2, Flavolipin, Figure 1), was first
isolated from Flavobacterium menigosepticum in 1988 [11,12]. F. menigosepticum is an opportunistic
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pathogen able to cause neonatal meningitis and nosocomial infections in immunocompromised
individuals [13]. Stereo-controlled synthesis of 2 and bioactivity testing revealed that its observed
macrophage activating effect [14] is triggered stereospecifically by the l-serine dipeptide lipid
N-[N-[(3R)-15-methyl-3-(13-methyltetradecanoyloxy)hexadecanoyl]glycyl]-L-serine, showing the same
bioactivity as natural 2 [12]. An early investigation suggested that 2 was a Toll-like receptor 4 ligand [15],
but recent investigations have shown that it acts as ligand on human and murine Toll-like receptor
2 (TLR-2) [16]. Compound 1 (Figure 1) is also shown to trigger TLR-2 [16]. The structures of both
lipids (Figure 1) have been verified by total synthesis [17]. In the previously mentioned study, 1 and
2 were isolated from Porphyromonas gingivalis. The pathogen is reported to be a virulence factor in
destructive periodontal disease, and lipids, such as dihydroceramides, have been shown to be involved
in TLR-2 mediated inflammation and inhibition of osteoblast differentiation [18,19]. Compounds 1 and
2 also inhibit osteoblast differentiation and function. Notably, the effect of 2 is mediated trough TLR-2
while the effect of 1 on osteoblasts is only partly mediated via TLR-2, indicating another target for 1 in
osteoblasts beside TLR-2 [20]. Due to that, serine-dipeptide lipids, together with sphingolipids, are
suggested to be virulence factors of P. ginvialis [21]. Interestingly, all those lipids likely to be virulence
factors share the attribute of an isobranched aliphatic fatty acid as a common feature, but they have
a large degree of variation in the head groups [21]. It has been shown that 1 and 2 are produced by
commensal oral and intestinal bacteria of the Bacteroidetes phylum, and they can be detected in human
tissue samples [22]. Notably, 2 is stereospecifically deacetylated by phospholipase 2, yielding a free
fatty acid and 1 [17,23].
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Figure 1. The two serine dipeptide lipids i i 430 (1) and Lipid 654 (2), acc rding to [16].
In the present study, we investigated two marine Algibacter sp. isolates for anti-microbial and
anti-cancer activities. Dereplication of the bioactive extracts revealed that both contained the same
unidentified compoun and the purifica ion of the comp nd led to the solation and ide tification of
the lipopeptide 1 from both Algibacter strains. The previously unknow anti-bacterial effect against
S. agalactiae was investigated and its cytotoxicity against lung fibroblasts and two cancer cell lines
was assessed.
2. Results
2.1. High Troughput Screening and Identification of the Strains
Through an in house high-throughput screening campaign where marine microorganisms were
cultivated, extracted, fractionated and screened for potential anti-cancer and anti-microbial activities,
two strains showed anti-microbial activity. Sequencing of the 16S rRNA and nucleotide blast against
16S ribosomal RNA sequences revealed that the strains M09B557 and M09B045 belong to the genus
Algibacter (Sequences in Appendix A). Strain M09B557 was isolated from the bryozoan Alcyonidium
gelatinosum and strain M09B045 was isolated from a soft coral commonly called “sea strawberry”
(Gersemia rubiformis), both sampled in the Barents Sea.
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2.2. Bioactivity Screening and Dereplication
The strains were recultivated in three 300 mL cultures each to produce sufficient material for
confirming the bioactivity detected in the previous high throughput screening campaign. The raw
extracts were fractionated into six fractions using reversed phase flash liquid chromatography and
subsequently tested in cell-based anti-microbial and anti-cancer assays. At concentrations of 200 and
100 µg/mL, respectively, an anti-bacterial effect of fraction five from both extracts against Streptococcus
agalactiae was detected (see Figure 2), while no cytotoxic effect was observed against A2058 melanoma
cells at a concentration of 200 µg/mL. The six flash fractions from each extract were analyzed using
UHPLC-HR-MS, and the active fractions five were compared with the “flanking” inactive fractions
four and six in an attempt to identify the component(s) responsible for the observed bioactivity. By
comparing the MS data of the active fraction with the flanking fractions it is possible to identify
compounds that are only present in the active fraction or there in the highest abundance. In addition,
extracts of the growth media were prepared according to the same protocol as used for bacterial
cultures. The media references were fractionated and analyzed via UHPLC-HR-MS to be compared to
the extracts in order to exclude media-components present within the bacterial extracts. Compounds
that were unique to the active fraction or present in higher amounts than in the inactive fractions,
were further investigated by calculation of elemental compositions, and along with the MS-fragments,
they were used for database searches. Using this approach, we were able to identify a candidate with
a positive ion mass of m/z 431.3103 and retention time of 8.28 min present in fraction five from the
extracts of both M09B557 and M09B045.
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Figure 2. Anti-bacterial effect of the fractions generated by flash liquid chromatography from extracts
of the cultures of the two Algibacter strains M09B045 and M09B557. Note that the tested assay
concentrations are different for the two strains but the purpose of the test was to identify candidates for
isolation rather than quantitative comparison of bioactivity.
2.3. Isolation of Lipid 430
For isolation of 1, 16 × 450 mL of M09B557 and 12 × 450 mL of M09B045 were cultivated, extracted
and fraction ed. The resulting flash fraction five from each extract was pool d, dried an dissolv
in DMSO (40 mg/mL) and hen diluted 1:4 (v/v) in meth nol. For the first HPLC-purification tep, a
column with C-18 functionalize stationary phase was employed. Different gradients were us d to
purify the target compound with fraction collection triggered by retent on time. The collect d fractions
we e reduced to dryness by vacuum centrifugation and redissolved in methanol. For the secon
HPLC-purification st p a fluorophen l col mn in combination with mass gui ed fractio triggering
was chosen. The final y eld of the is lated comp und were 1.7 mg fr m M09B045 and 2.3 mg from
M09B557. The purities of the preparati ns were tested using UHPLC-HR-MS and the two s mples
were pooled. The chromatograms (BPI and extracted ion chromato ram as well as A254nm) of the
purity test are given in the Supplementary Information (Figure S1).
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2.4. Structure Elucidation via NMR and MS/MS Analysis
Through 1D (1H, 13C, Table 1) and 2D (HMBC, HSQC, H2BC, COSY, Figure 3 and Figures S2–S6
in the Supplementary Information) data recorded for 1, the compound was confirmed to be Lipid 430.
Due to significant overlap of the central CH2 groups (13-CH2 to 19-CH2), in agreement with what has
previously been observed for 1 as well as the ester-linked iso C15:0 variant of 1 [16], these methylene
groups could not be unambiguously assigned by NMR, though the integral sum of the unresolved
region was consistent with the expected number of contributing protons. Based on HR-MS/MS the
elemental composition was calculated to be C22H42N2O6 (m/z 431.3112 [M + H]+ in ESI+, calcd 431.3121
and 429.2970 [M − H]− in ESI−, calcd 429.2965). Taking the MS results and the NMR spectra together,
the proposed structure is the only conformation that fits both datasets.
Table 1. 1H and 13C assignments for “Lipid 430 (1)” (see Figure 3) (1H 600 MHz, 13C 150 MHz, CD3OH).
Lipid 430 (1)
Position δC, Type δH (J in Hz)
1 173.8, C
2 56.5, CH 4.47, dt (8.2, 4.2)
3a 63.2, CH2
3.89, dd (9.3, 5.2) ) c
3b 3.82, dd (11.3, 3.9)
4 7.99, d (7.8)
5 171.5, C
6a 43.6, CH2
3.98, dd (16.7, 5.9) b
6b 3.89, dd (9.3, 5.2) c
7 8.31, t (5.9)
8 175.0, C
9a 44.8, CH2
2.40, dd (13.9, 4.1)
9b 2.33, dd (14.0, 8.8)
10 70.0, CH 3.98, dd (16.7, 5.9) b
11 38.3, CH2 1.50–1.47, m
12 26.5, CH2 1.47–1.42, m
13 30.9–30.6 a, CH2 1.29, p (6.1, 5.4) e
14 30.9–30.6 a, CH2 1.29, p (6.1, 5.4) e
15 30.9–30.6 a, CH2 1.29, p (6.1, 5.4) e
16 30.9–30.6 a, CH2 1.29, p (6.1, 5.4) e
17 30.9–30.6 a, CH2 1.29, p (6.1, 5.4) e
18 30.9–30.6 a, CH2 1.29, p (6.1, 5.4) e
19 30.9–30.6 a, CH2 1.29, p (6.1, 5.4) e
20 28.4, CH2 1.29, p (6.1, 5.4) e
21 40.1, CH2 1.16, q (7.1, 6.7)
22 29.0, CH 1.56–1.50, m
23 22.9, CH3 0.87, d (6.6) d
24 22.9, CH3 0.87, d (6.6) d
a–e Signals are overlapping.














































Figure 3. The structure of the isolated compound Lipid 430 (1) (A) and 2D-NMR correlations measured
fro our isolated sample (B). In B, sel cted COSY correlations are indicated in bold bonds a d selected
HMBC correlations are shown as arrows. The structure proposed upon the NMR data complies with
Lipid 430 (1).
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2.5. Anti-microbial effect of Lipid 430
Compound 1 was tested for anti-bacterial activity against S. aureus, E. coli, E. faecialis, P. aeruginosa,
S. agalactiae and Methicillin resistant S. aureus (MRSA) at concentrations of 50, 25, 10, 5, 2.5 and 1 µg/mL,
equal to molar concentrations of 116, 58, 23, 12, 6 and 2 µM, respectively. The tests were conducted
twice, using two technical replicates in two independent experiments for S. agalactiae. A significant
effect on S. agalactiae and MRSA was observed, see Figure 4. The calculated IC50 of 1 against S. agalactiae
was 30 µM or 13 µg/mL respectively. At a concentration of 58 µM the growth of S. agalactiae was
completely inhibited. For MRSA the IC50 was not determined as the highest tested concentration
of (1) (116 µM or 50 µg/mL) reduced growth by 38%. To test if the observed effect on S. agalactiae
was bactericidal or bacteriostatic, the 100 µL incubation volume of the growth assay for 58 µM 1 was
streaked out further on brown agar and incubated at 37 ◦C. No colony or sign of bacterial growth
was visible after 4 days of incubation (two technical replicates). There were no colonies formed after
incubation with the compound, which indicated that 1 exerted bactericidal effect against S. agalactiae at
a concentration of 58 µM.
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Figure 4. Anti-microbial effect of Lipid 430 (1) on S. agalactiae (two technical replicates in two
experiments) and MRSA (two technical replicates). IC50 for S. agalactiae was 30.16 µM using a sigmoidal
fit (Span ± 0.91 µM; Degrees of Freedom 20; R squared 0.97; Adjusted R squared 0.97, Sum of squares
0.13). IC50 of MRSA is >116 µM and was not determined.
2.6. Cytotoxic Effect of 1
2.6.1. Cytotoxicity Assay
The effect of 1 was tested against three human cell lines, the melanoma cell line A2058, the
colon carcinoma cell lin HT29 nd the lung fibroblast cell line MRC5. The compound was t sted at
concentr tions of 100, 75, 50, 25, 10 and 5 µg/mL equal to molar concentrati ns of 233, 175, 116, 58, 23
a d 12 µM, respectively. There was o significant effect observed against the lung fibroblast or colon
carcinoma cells at the tested concentrations. The results for all tested cell lines and positive controls are
shown in the Supplementary Information (Figure S7). For the melanoma cell line, a dose dependent
cytotoxic effect was observed, see Figure 5. The IC50 of 1 against the melanoma cell line was calculated
to be 175 µM (75 µg/mL). The test was executed in two independent experiments with three technical
replicates each.
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Figure 5. Cytotoxic effect of Lipid 430 (1) against the A2058 melanoma cell line. A linear correlation
with % Survival = −0.00332c+1.08 {c ∈ R | c ≥ 12 µM ˆ c ≤ 233 µM} was found (R square 0.93, Sy.x
0.07442). The 95% Confidence intervals are shown in dot lines. The calculated IC50 for 1 in the linear
model is 175 µM.
2.6.2. Propidium Iodide Staining and Flow Cytometry
To investigate whether the cytotoxic effect of 1 was mediated by affecting the integrity of the cell
membrane, propidium iodide (PI) staining in combination with flow cytometry was employed. PI is
indicating integrity of the cell membrane by passing through damaged me branes and intercalating
into the DNA. As a positive control, TritonX™was tested at concentrations of 0.005, 0.01 and 0.05%.
(v/v). Compound 1 was tested at concentrations of 20, 50 and 100 µM. The results are shown in
Figure 6. The PI positive cells indicate the population of cells with affected cell membranes increasing
with the concentration of the detergent TritonX. For 1, no tendency was observable (see Figure 6A).
The exemplary dot plot graphs of the Control and of 100 µM 1 support this assumption (see Figure 6B,C).
Due to the limited amount of compound, the experiment was carried out only once, this should be
considered critically when interpreting the gained data. The dot plot graphs for all conditions are
given in the Supplementary Information S8.
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Figure 6. Results of the flow cytometry experiments with melanoma cell line A2058. In (A) the relative
ratio between PI positive (+) and PI negative (−) is shown. The exact results are the following: stained
control (Ctrl.), 8.46% PI+; 0.01% TritonX, 27.61% PI+; 0.05% TritonX, 87.38% PI+; 20 µM 1, 9.45% PI+;
50 µM Lipid 430, 11.26% PI+; 100 µM Lipid 430, 8.72% PI+. (B) depicts the flow cytometry results as
dot plot graph of the stained control and in (C) a dot plot graph of the cells threated with 100 µM 1
is given. Forward scatter is displayed on the X-axis and propidium iodide absorption on the Y-axis.
The relative ratio of events is given in %.
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2.6.3. Microscopic Investigation of the Melanoma Cell Line A2058
For the microscopic examination, the cells were exposed for 4 h to concentrations of 100- and
500 µg/mL of 1, equal to molar concentrations of 233 µM and 1165 µM, respectively. In both cases,
no morphological difference between the treatment and the control could be observed at 100×
magnification. Microscopic pictures of the investigation are shown in the Supplementary Information
(Figure S9).
2.7. Lipid Isolation, Detection of Lipid 654
Compound 1 is known to be a de-acetylation product of 2 catalyzed by phospholipases. Likewise,
1 could be the biosynthetic predecessor of 2 trough esterification of 1. Therefore, the raw extracts of
both bacteria were analyzed using UHPLC-HR-MS in order to look for 2, but no mass signal was found
that could be related to 2. To ensure that the absence of 1 was not a result of the extraction protocol
using HP-20 beads, chloroform extraction was executed with cultures of both strains. The chloroform
extracts were analyzed using UHPLC-HR-MS, but no signals potentially related to 2 were detected.
3. Discussion
The active principle of the two extracts from two Algibacter isolates was identified and investigated
upon its bioactivity towards bacteria and mammalian cell lines. The observed anti-bacterial effect
of 1 against Streptococcus agalactiae was higher compared to the pathogen MRSA which possessed
a significantly higher tolerance against 1. Notably, S. agalactiae was the most sensitive among the
tested bacterial strains. When screening the bacterial extracts, we frequently observed that fractions
containing for instance phosphocolines or rhamnolipids were active against S. agalactiae while no or
only weak activities were observed against the other bacteria (data not shown) [24]. The sensitivity
of the melanoma cell line against 1 was significantly (at least seven times) lower compared to the
anti-bacterial effect against S. agalactiae. Furthermore, no effects were observed on colon carcinoma
cells and lung fibroblasts. This corresponds well with the observation that the initial screening of the
flash fractions of the crude extracts did not show activity in the anti-cancer assays while it did in the
anti-microbial assays.
The fact that 1 showed activity against the bacterial strain and cancer cell line that in our experience
are most sensitive to surfactants gives rise to the suspicion that the compound is affecting the integrity
of the cell membranes in an unspecific way. Given the known bioactivity of 1, being a ligand to
TLR-2 on one hand and the structure of the molecule on the other one, it was questionable if the
cytotoxic effect was mediated by lysing the cells. The aliphatic, iso-branced fatty acid with a polar
head consisting of two amino acids could suggest that it acts as surfactant. Therefore, PI staining
followed by flow cytometry analysis was done to check if the lipid affected the membrane integrity of
melanoma cells. This turned out to not be the case for any of the tested concentrations. PI staining is
a technique capable of staining cells with reduced membrane integrity that can be detected by flow
cytometry [25,26] with high linearity [27]. We used TritonX™ as detergent to test the suitability of the
method. However, we did not observe a cellular effect after one hour of incubation with propidium
iodide when analyzed with flow cytometry or after 4 h when inspecting the cells in the microscope, at
least not at the tested concentrations. The effect we detected in the cytotoxicity assay was observed
after 72 h of incubation with 1, conclusively the effect is taking place during a longer incubation time
maybe affecting cell division or cell cycle.
It is known that lipopeptides have a broad spectrum of activity including anti-fungal, anti-bacterial,
anti-cancer and anti-inflammatory effects [28–30]. The lipopeptide antibiotic daptomycin is used
to treat infections by Gram positive bacteria and was introduced into the marked in 2001 [31].
Surfactin, a lipopeptide with high surfactant power [32], exhibits also various bioactivities such as
anti-inflammatory, anti-cancer and thrombolytic bioactivities [30]. The anti-bacterial and cytotoxic
mode of action of both compounds relies on affecting the integrity of the cell membrane of target
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cells [30,33]. However, those two marketed lipopeptides differ significantly from 1. Daptomycin is a 13
amino acid cyclic lipopeptide (10 amino acids forming a ring structure) linked to decanoic acid [34]
while Surfactin consists of a seven aminoacid cycle, linked to a 13−15 carbon chain [35]. Note that
there are also linear lipopeptides as for example gageostatins, isolated from a marine Bacillus, showing
similar bioactivities [36]. However, the mentioned cyclic lipopeptides differ greatly from the linear
two-amino acid 1 in structure and molecular mass. Even the Gageostratins with an Mw > 1000 u appear
to be rather distant relatives. It seems more appropriate to consult the results of Makovitzki et al. [37]
who investigated synthetic lipo-tetrapeptides linked to C-12, C-14 and C-16 fatty acids. They observed
varying anti-fungal, anti-bacterial and hemolytic activities depending on the respective peptide
sequence and length of the fatty acid chain. Their effect in vivo corresponded with the respective
lipopeptide’s ability to disrupt the membrane of the respective organisms, indicating a membranolytic
mode of action. Taking that together, 1 rather seemed to be a candidate for membranolytic bioactivity.
Its anti-bacterial effect varies between the species and already between the two Gram positive bacteria
MRSA and S. agalactiae. Taking all together, we conclude that 1 is not lysing the cells or affecting their
integrity immediately. Taking the general bioactivity of lipopeptides into account, mostly affecting the
cell membrane, possibly the lipid is interfering with the membrane during cell division, representing a
more fragile state of cell integrity. It would be valuable to investigate its effect on melanoma cells more
in detail, which was not possible in the present study due to a limited quantity of 1.
After isolating 1, the extracts of the bacterial fermentations were investigated upon the presence
of the related Lipid 654 (2). The UPLC-MS/MS profiles of the solid phase extracts have not shown
any signal that indicated the presence of 2. However, it was reported that 2 is soluble in chloroform.
To exclude that the lack of 2 was caused by unsuitability of solid phase extraction for that compound,
we used chloroform liquid–liquid phase extraction and UHPLC-HR-MS to investigate its presence
with negative outcome.
The natural role of Algibacter, being decomposers degrading algal biomass, may suggests that 1
is produced as a surfactant for mobilizing nutrients, in a similar way as the rhamnolipids do [38,39].
An additional role, or side effect, as an antibacterial agent cannot be excluded. There is no indication
that the water insoluble Compound 2 is produced by the two Algibacter strains under the selected
conditions; this could support the hypothesis that 1 is produced as a surfactant to mobilize hydrophobic
nutrients. It furthermore supports the hypothesis that 1 is the biosynthetic precursor of 2 [17].
4. Materials and Methods
4.1. Bacterial Isolates
Two Algibacter sp. strains were isolated from organisms collected in the Barents Sea. Strain
M09B557 was isolated from Alcyonidium gelatinosum sampled at 28.05.2009 at 70◦6,60000’ N and
28◦56,206190’ E. Strain M09B045 was isolated from Gersemia rubiformis sampled at the 14.05.2019 at
78◦7,80000’ N and 13◦34,962001’ E. The bacteria were isolated from the surface of the animals after
washing them under filtrated seawater. Using a inoculation loop the surface of the organisms was
sampled and potentially adhering bacteria were streaked out on FMAP agar, prepared of: 15 g Difco
marine broth (Becton, Dickinson and Company, Franklin Lakes, NJ, USA), 15 g agar (Sigma, St. Louis,
Mo, USA), 5 g peptone (Sigma), 700 mL ddH2O and 300 mL filtrated seawater. For storage of the
isolates, liquid FMAP media was inoculated with the respective strain, grown until turbidity of the
media was visible and cryo-conserved at −80 ◦C after adding 30% (v/v) glycerol (Sigma).
4.2. PCR and Identification of the Strains
The cryo-conserved isolates were plated out on FMAP agar in petri dishes and cultivated at 10 ◦C.
After 7 d, colonies were picked and dissolved with 100 µL ddH2O in an Eppendorf tube. The sample
was subsequently boiled for 5 min to break up the cells. For PCR, 1 µL of the bacterial lysate was
used for a PCR reaction of 25 µL with 1 µM of forward and reverse primer (forward primer: 27F,
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AGAGTTTGATCMTGGCTCAG; reverse primer: 1492rR, CGGTTACCTTGTTACGACTT) and 12,5 µL
ThermoPrimeTM 2 × ReddyMix PCR master mix (ThermoFisher Scientific, Waltham, MA, USA).
The reactions were amplified using an Mastercycler epgradient S (Eppendorf, Hamburg, Germany)
with the following program: 95 ◦C initial denaturation for 5 min followed by 30 cycles of 94 ◦C for
30 s, 55 ◦C for 30 s and 72 ◦C for 1 min. Final extension was at 72 ◦C for 10 min. Afterwards the
PCR reaction was analyzed for purity on a 1.0% agarose gel and the results were documented using a
Syngene Bioimaging system. For purification of the 16S rRNA gene PCR amplificate the QIAquick
PCR purification kit was used according to manufacturer’s instructions (QIAGEN, Hilden, Germany).
The PCR product purified from the gel was sequenced at the University Hospital of North Norway
(Tromsø, Norway) employing the two primers mentioned above. For sequence homology comparison
the online Basic Local Alignment Search Tool (BLAST) was used (www.ncbi.nlm.nih.gov/BLAST).
The strains were identified according to their phylogenetic interference.
4.3. Fermentation and Extraction of Algibacter Cultures
M09B557 was cultivated in 1 L Warburg flasks containing 450 mL modified DSGC medium for 7 d
at 130 rpm and 10 ◦C. M10B738 was cultivated for 12 d under the same conditions in 1 L Warburg flasks
containing 450 mL DVR1 medium. Modified DSGC medium was prepared of 1 L filtrated seawater,
4.0 g d-glucose (Sigma) and 3.0 g Peptone (from casein, enzymatic digest, Sigma). DVR1 medium was
prepared from 0.5 L filtrated seawater, 0.5 L ddH2O, 6.7 g malt extract (Sigma), 11.1 g Peptone (from
casein, enzymatic digest, Sigma) and 6.7 g yeast extract (Sigma). All media were autoclaved at 120
◦C for 30 min. The filtrated seawater was prepared by filtrating seawater through a Millidisk® 40
Cartridge with Durapore® 0.22 µm filter membrane (Millipore, Burlington, MA, USA).
For extraction of metabolites, solid phase extraction using Diaion®HP-20 resin (13607, Supelco
Analytica, Bellefonte, PA, USA) was executed. The resin had been activated by incubation in methanol
for a minimum of 30 min and washed with ddH2O for 15 min. 40 g of resin were added to 1 L of culture
three days before the culture was harvested. The resin was separated from the fermentation broth by
vacuum filtration using a cheesecloth mesh (1057, Dansk Hjemmeproduktion, Ejstrupholm, Danmark)
to restrain the resin. Thereafter the resin was washed with 100 mL of ddH2O to remove remaining
fermentation broth. The molecules bound to the resin were eluted with 150 mL methanol (HiPerSolv,
VWR, Radnor, Penns., USA) per 40 g resin (shaking at 130 rpm for 30 min) and vaccuumfiltration using
Whatman No. 3 filterpaper (Whatman plc, Buckinghamshire, UK). The elution from the resin was
done twice and the methanolic extract was dried under reduced pressure at 40 ◦C and stored at −20 ◦C
upon further processing.
4.4. Fractionation
Crude extracts were fractionated using flash liquid chromatography. The extracts were loaded
onto resin (Diaion® HP-20ss, Supelco) by dissolving them in 90% methanol aq. (v/v) and adding resin
in a ratio of 1:1.5 (resin/dry extract, w/w). Subsequently, the solution was dried under reduced pressure
at 40 ◦C. Flash columns (Biotage® SNAP Ultra, Biotage, Uppsala, Sweden) were prepared by activating
the resin by incubation in methanol for 20 min, washing with ddH2O and loading it into the column
ensuring the resin being always covered with water. 6.5 g HP-20ss resin was loaded on one column.
The fractionation was performed using a Biotage SP4™ system and a water: methanol gradient from
5–100% methanol over 36 min (6 min 5% B, 6 min 25% B, 6 min 50% B, 6 min 75% B, 12 min 100% B)
followed by a methanol: acetone step-gradient (4 min methanol, 12 min acetone). The flow rate was
set to 12 mL/min. 27 eluent fractions to 24 mL each were collected in glass tubes and pooled to six flash
fractions in total (1–3 were pooled to fraction 1; 4–6 to fraction 2; 7–9 to fraction 3; 10–12 to fraction 4;
13–15 to fraction 5; 16–27 to fraction 6). An appropriate amount of extract-resin mixture was loaded
onto the column after equilibration to 5% methanol aq. (v/v). The flash fractions were dried under
reduced pressure at 40 ◦C.
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4.5. UHPLC-HR-MS and Dereplication
UHPLC-HR-MS data for dereplication was recorded using an Acquity I-class UPLC (Waters,
Milford, MA, USA) coupled to a PDA detector and a Vion IMS QToF (Waters). The chromatographic
separation was performed using an Acquity C-18 UPLC column (1.7 µm, 2.1 mm × 100 mm) (Waters).
Mobile phases consisted out of acetonitrile (HiPerSolv, VWR) for mobile phase A and ddH2O produced
by the in-house Milli-Q system as mobile phase B, both containing 1% formic acid (v/v) (33015, Sigma).
The gradient was run from 10% to 90% B in 12 min at a flow rate of 0.45 mL/min. Samples were run in
ESI+ and ESI- ionization mode. The data was processed and analyzed using UNIFI 1.8.2 (Waters).
4.6. Isolation of Lipid 430
Purification of compound 1 was done using a semi preparative HPLC system (Waters) made
up by a 600 HPLC pump, a 3100 mass spectrometer, a 2996 photo diode array detector and a 2767
sample manager. A 515 HPLC pump and a flow splitter were used to infuse the analytes into the MS.
The mobile phases were degassed by an in-line degasser. For controlling the system, the software
MassLynx™ 4.1 (Waters) was used. The columns used for isolation were X-Terra RP-18 preparative
column (10 µm, 10 mm × 250 mm) and XSelect CSH preparative Fluoro-Phenyl column (5 µm, 10 mm
× 250mm), both columns were purchased from Waters. The mobile phases for the gradients were A
[ddH2O with 0.1% (v/v) formic acid] and B [acetonitrile with 0.1% (v/v) formic acid], flow rate was set to
6 mL/min. Acetonitrile (Prepsolv®, Merk KGaA, Darmsatdt, Germany) and formic acid (33015, Sigma)
were purchased in appropriate quality, ddH2O was produced with the in-house Milli-Q® system. For
the MS-detection of the eluting compounds one percent of the flow was split from the fractions in line,
blended with 80% Methanol in ddH2O (v/v) acidified with 0.2% Formic acid (Sigma) and directed to
the ESI-quadrupole-MS.
4.7. NMR Spectroscopy
All NMR spectra were recorded on a Bruker Avance III HD spectrometer equipped with an inverse
detected TCI probe with cryogenic enhancement on 1H, 2H and 13C. The operating frequencies were
599.90 MHz for 1H and 150.86 MHz for 13C. The samples were prepared in methanol-d3 and recorded
at 298 K.
All experiments were recorded using standard pulse sequences for Proton, Presat, Carbon,
DQFCOSY, HSQC, HMBC, H2BC, NOESY and ROESY (gradient selected and adiabatic versions, with
matched sweeps where applicable) in Topspin 3.5pl7 and processed in Mnova 12.0.0. Spectra were
referenced on the residual solvent peak of methanol-d3 (δH = 3.31 and δC = 49.00).
4.8. Lipid Extraction
Total lipids were extracted by shaking 25 mL of bacterial culture with 25 mL chloroform (EMSURE®,
Merck) in screw cap centrifuge tubes (21008-242, VWR) for 3 h at 40 rpm using a tube-rotator (SB3,
Stuart, Stone, UK). Afterwards the organic phase was separated and centrifuged for 10 min at 4600
rpm (Multifuge 3, rotor 75006445, S-R, Heraeus, Hanau, Germany) to remove debris and particles.
Thereafter the organic phase was vacuum filtrated trough Whatman No. 3 filter paper (Whatman) and
concentrated to 5 mL under nitrogen.
4.9. Anti-Microbial Assays
4.9.1. Growth Inhibition Assay
To determine and quantify anti-microbial activity, a bacteria growth inhibition assay in liquid
media was executed. The samples were tested against S. aureus (ATCC 25923), E. coli (ATCC 259233),
E. faecialis (ATCC 29122), P. aeruginosa (ATCC 27853), S. agalactiae (ATCC 12386) and Methicillin resistant
S. aureus (MRSA) (ATCC 33591). S. aureus, MRSA, E. coli and P. aeruginosa were grown in Muller Hinton
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broth (275730, Becton, Dickinson and Company). E. facalis and S. agalactiae were cultured in brain hearth
infusion broth (53286, Sigma). Fresh bacteria colonies were transferred in the respective medium and
incubated at 37 ◦C over night. The bacterial cultures were diluted to a culture density representing the
log phase and 50 µL/well were pipetted into a 96-well microtiter plate (734-2097, Nunclon™, Thermo
Scientific, Waltham, MA, USA). The final cell density was 1500–15,000 CFU/well. Flash fractionated
extracts were diluted in 1% (v/v) dimethyl sulfoxide (DMSO, D4540, Sigma). Pure compound was
diluted in 2% (v/v) DMSO in ddH2O, the final assay concentration was 50% of the prepared sample,
since 50 µL of sample in DMSO/water were added to 50 µL bacterial culture. After adding the samples
to the plates, they were incubated over night at 37 ◦C and the growth was determined by measuring
the optical density at λ = 600 nm (OD600) with a 1420 Multilabel Counter VICTOR3™ (Perkin Elmer,
Waltham, MA, USA). A water sample was used as reference control, growth medium without bacteria
was used as a negative control and a dilution series of gentamycin (A2712, Merck) from 32 to 0.01 µg/mL
was used as positive control and visually inspected for bacterial growth. The positive control was used
as system suitability test and the results of the antimicrobial assay were only considered valid when
positive control was passed. The final concentration of DMSO in the assays was ≤ 2% (v/v) known to
have no effect in the tested bacteria. The data was processed using GraphPad Prism 8.
4.9.2. Bactericidal Assay
For investigation of bactericidal effect, the 100 µL reactions of the S. agalactiae anti-microbial
assay were streaked on brown agar plates (University hospital of northern Norway, Tromsø, Norway)
and incubated for four days at 37 ◦C, the plates were visually investigated after 1 day and 4 days
of incubation.
4.10. Cell Proliferation Assay
The inhibitory effect of fractions and compounds was tested using an MTS in vitro cell
proliferation assay against two cancer cell lines and one normal cell line. The cancer cell
lines were human melanoma A2058 (ATCC, CLR-1147™) and human colon carcinoma HT29
(ATCC HTB-22™), as cell line for the general cytotoxicity assessment, non-malignant MRC5
lung fibroblast cells (ATCC CCL-171™) were employed. The cells were cultured and assayed
in Roswell Park Memorial Institute medium (RPMI-16040, FG1383, Merck) containing 10% (v/v)
Fetal Bovine serum (FBS, 50115, Biochrom, Cambridge, UK). The cell-concentration was 4000
cells/well for the lung fibroblast cells and 2000 cells/well for the cancer cells. After seeding,
the cells were incubated 24 h at 37 ◦C and 5% CO2. The medium was then replaced with
fresh RPMI-1640 medium supplemented with 10% (v/v) FBS and gentamycin (10 µg/mL, A2712,
Merck). After adding 10 µL of sample diluted in 2% (v/v) DMSO in ddH2O the cells were
incubated for 72 h at 37 ◦C and 5% CO2. For assaying the viability of the cells 10 µL of CellTiter
96®AQueous One Solution Reagent (G3581, Promega, Madison, WI, USA) containing tetrazolium
[3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner
salt] and phenazine ethosulfate was added to each well and incubated for one hour. The tests were
executed with three technical replicates. The plates were read using a DTX 880 plate reader by
measuring the absorbance at λ = 485 nm. The cell viability was calculated using the media control.
As a negative control RPMI-1640 with 10% (v/v) FBS and 0.5% Triton™ X-100 (Sigma-Aldrich) was
used as a positive control. The data was processed and visualized using GraphPad Prism 8
4.11. Mode of Action Studies
4.11.1. Flow Cytometry
For the investigation of the mode of action of 1 on the A2058 cells, cells were seed in six well
plates (Nunclon™, Thermo Fisher) with a density of one million cells in three mL of Eagle’s medium
(Dulbecco’s modified Eagles medium, D6171, Sigma) with 10% (v/v) FBS. Cells were incubated over
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night at 37 ◦C and 5% CO2 and medium was exchanged to two mL Eagle’s medium, the respective
amount of compound or Triton™ X-100 (Sigma-Aldrich) as positive control, propidium iodide (Sigma)
to a final concentration of 5 µg/mL and the wells were filled up to 3 mL with phosphate buffered
saline (PBS, Dulbecco’s PBS, D8537, Sigma). One unstained control without propidium iodide and one
negative control without compound were prepared. The reactions were incubated for 1 h at 37 ◦C and
5% CO2, media was removed, the cells were spilled with PBS buffer and trypsinated using 400 µL of
trypsine solution (Trypsin-EDTA 10 ×, Biowest, Nuaillé, France) and redissolved in 1 mL of PBS with
propidium iodide (5 µg/mL). The cell suspensions were transferred into sample tubes and analyzed
using a Cytoflex flow cytometer (Beckman Coulter, Brea, Cal., US) and CytExpert.
4.11.2. Microscopic Investigation of Melanoma Cells
For the microscopic investigation of melanoma cells, the A2058 cells were seed out in Eagle’s
medium at a concentration of 2000 cells/well in 100 µL medium per well. The cells were incubated
over night at 37 ◦C and 5% CO2. The media in the wells was replaced with 50 µL Eagle’s medium,
compound 1 was added and the wells were filled up with PBS to a total volume of 100 µL. The reactions
were incubated at 37 ◦C and 5% CO2 for 4 h, 50 µL of media were removed and replaced with 50 µL of
0.4% Trypan blue solution (Sigma) and incubated at room temperature for three minutes. Then the
media with Trypan blue was removed, leaving the bottom of the wells covered with a thin liquid layer
and examined microscopically at a magnification of 10 × 10 (Leica DMIC, Leica, Germany). Pictures
were taken using a microscope camera (Marlin F-046B IRF, Allied vision, Germany).
5. Conclusions
It was shown that two strains of the genus Algibacter were capable of producing Lipid 430 (1).
The bioactivity of 1 seems to be comparable to other lipopeptides such as synthetic lipo-tetrapeptides.
It showed cytotoxicity against melanoma cells with a IC50 concentration of 175 µM after 72 h of
incubation, the exact mode of action remains to be investigated but our experimental results indicate
that 1 did not lyse the cells immediately. The IC50 concentration against S. agalactiae was determined to
be 30 µM, at a concentration of 58 µM it was shown to be bactericidal against S. agalactiae. To the best
of our knowledge, this is the first report of bioactive compounds isolated from the genus Algibacter.
Supplementary Materials: The following are available online, Figure S1: purity analysis of prepared compound
1, Figure S2: 1H NMR spectrum of 1, Figure S3: 13C NMR spectrum of 1, Figure S4: HSQC + HMBC spectrum of
1, Figure S5: COSY spectrum of 1, Figure S6: H2BC spectrum of 1, Figure S7: results of the cytotoxicity assays,
Figure S8: results of the flow cytometry experiments, Figure S9: pictures of the microscopic investigation of
melanoma cells.
Author Contributions: Y.K.-H.S. fermented and extracted the cultures, dereplicated and isolated the compound;
J.I., K.Ø.H. and Y.K.-H.S. elucidated the structure; S.U. and Y.K.-H.S. planned and executed the investigation of
the cytotoxicity; J.H.A., E.H.H. and Y.K.-H.S. designed the study; Y.K.-H.S., K.Ø.H., E.H.H. and J.H.A. prepared
the manuscript.
Funding: This project received funding from the Marie Skłodowska-Curie Action MarPipe, grant agreement GA
721421 H2020-MSCA-ITN-2016, of the European Union and from UiT – The Arctic University of Norway.
Acknowledgments: The authors want to acknowledge our colleagues from The Norwegian Marine Biobank
(Marbank) for isolation and identification of the bacterial strains. Marte Albrigtsen and Kirsti Helland are gratefully
acknowledged for execution of the bioassays and their help in solving many experimental issues.
Conflicts of Interest: The authors declare no conflict of interest.
Appendix A
16S rRNA sequencing results
Molecules 2019, 24, 3991 13 of 15









































1. Kirchman, D.L. The ecology of Cytophaga-Flavobacteria in aquatic environments. FEMS Microb. Ecol. 2002,
39, 91–100. [CrossRef]
2. Fernández-Gómez, B.; Richter, M.; Schüler, M.; Pinhassi, J.; Acinas, S.G.; González, J.M.; Pedrós-Alió, C.
Ecology of marine Bacteroidetes: A comparative genomics approach. ISME J. 2013, 7, 1026–1037. [CrossRef]
3. Gómez-Pereira, P.R.; Fuchs, B.M.; Alonso, C.; Oliver, M.J.; Beusekom, J.E.E.; Amann, R. Distinct flavobacterial
communities in contrasting water masses of the north Atlantic Ocean. ISME J. 2010, 4, 472–487. [CrossRef]
4. Nedashkovskaya, O.I.; Kim, S.B.; Han, S.K.; Rhee, M.S.; Lysenko, A.M.; Rohde, M.; Zhukova, N.V.;
Frolova, G.M.; Mikhailkov, V.V.; Bae, K.S. Algibacter lectus gen. nov., sp. nov., a novel member of the family
Flavobacteriaceae isolated from green algae. Int. J. System. Evol. Microbiol. 2004, 54, 1257–1261. [CrossRef]
Molecules 2019, 24, 3991 14 of 15
5. Park, S.C.; Hwang, Y.M.; Choe, H.N.; Baik, K.S.; Kim, H.; Seong, C.N. Algibacter aquimarinus sp. nov., isolated
from a marine environment, and reclassification of Pontirhabdus pectinivorans as Algibacter pectinivorans comb.
nov. Int. J. System. Evol. Microbiol. 2013, 63, 2038–2042. [CrossRef]
6. Park, S.C.; Hwang, Y.M.; Lee, J.H.; Baik, K.S.; Seong, C.N. Algibacter agarivorans sp. nov. and Algibacter
agarilyticus sp. nov., isolated from seawater, reclassification of Marinivirga aestuarii as Algibacter aestuarii comb.
nov. and emended description of the genus Algibacter. Int. J. System. Evol. Microbiol. 2013, 63, 3494–3500.
[CrossRef]
7. Nedashkovskaya, O.I.; Vancanneyt, M.; Kim, S.B.; Hoste, B.; Bae, K.S. Algibacter mikhailovii sp. nov., a novel
marine bacterium of the family Flavobacteriaceae, and emended description of the genus Algibacter. Int. J.
System. Evol. Microbiol. 2007, 57, 2147–2150. [CrossRef]
8. Park, S.; Jung, Y.T.; Yoon, J.H. Algibacter miyuki sp. nov., a member of the family Flavobacteriaceae isolated
from leachate of a brown algae reservoir. Antonie Van Leeuwenhoek 2013, 104, 253–260. [CrossRef]
9. Yoon, J.H.; Park, S. Algibacter wandonensis sp nov., isolated from sediment around a brown algae (Undaria
pinnatifida) reservoir. Int. J. System. Evol. Microbiol. 2013, 63, 4771–4776. [CrossRef]
10. Sun, C.; Fu, G.; Zhang, C.; Hu, J.; Xu, L.; Wang, R.; Su, Y.; Han, S.; Yu, X.; Cheng, H.; et al. Isolation
and complete genome sequence of Algibacter alginolytica sp. nov., a novel seaweed-degrading Bacteroidetes
bacterium with diverse putative polysaccharide utilization loci. Appl. Environ. Microbiol. 2016, 82, 2975–2987.
[CrossRef]
11. Kawai, Y.; Yano, I.; Kaneda, K. Various kinds of lipoamino acids including a novel serine-containing lipid in
an opportunistic pathogen Flavobacterium. Eur. J. Biochem. 1988, 171, 73–80. [CrossRef]
12. Shiozaki, M.; Deguchi, N.; Mochizuki, T.; Wakabayashi, T.; Ishikawa, T.; Haruyama, H.; Kawai, Y.;
Nishijima, M. Revised structure and synthesis of Flavolipin. Tetrahedron 1998, 54, 11861–11876. [CrossRef]
13. Ratner, H. Flavobacterium meningosepticum. Inf. Contr. 1984, 5, 237–239. [CrossRef]
14. Kawai, Y.; Akagawa, K. Macrophage activation by an ornithine-containing lipid or a serine-containing lipid.
Inf. Immun. 1989, 57, 2086–2091.
15. Gomi, K.; Kawasaki, K.; Kawai, Y.; Shiozaki, M.; Nishijima, M. Toll-like receptor 4-MD-2 complex mediates
the signal transduction induced by Flavolipin, an amino acid-containing lipid unique to Flavobacterium
meningosepticum. J. Immun. 2002, 168, 2939–2943. [CrossRef]
16. Clark, B.R.; Cervantes, J.L.; Maciejewski, M.W.; Farrokhi, V.; Nemati, R.; Yao, X.; Anstadt, E.; Fujiwara, M.;
Wright, K.T.; Riddle, C.; et al. Serine lipids of Porphyromonas gingivalis are human and mouse toll-like receptor
2 ligands. Inf. Immun. 2013, 81, 3479–3489. [CrossRef]
17. Dietz, C.; Hart, T.K.; Nemati, R.; Yao, X.; Nichols, F.C.; Smith, M.B. Structural verification via convergent
total synthesis of dipeptide–lipids isolated from Porphyromonas gingivalis. Tetrahedron 2016, 72, 7557–7569.
[CrossRef]
18. Wang, Y.H.; Jiang, J.; Zhu, Q.; AlAnezi, A.Z.; Clark, R.B.; Jiang, X.; Rowe, D.W.; Nichols, F.C. Porphyromonas
gingivalis lipids inhibit osteoblastic differentiation and function. Infect. Immun. 2010, 78, 3726–3735.
[CrossRef]
19. Nichols, F.C.; Housley, W.J.; O’Conor, C.A.; Manning, T.; Wu, S.; Clark, R.B. Unique lipids from a common
human bacterium represent a new class of toll-like receptor 2 ligands capable of enhancing autoimmunity.
Ame. J. Pathol. 2009, 175, 2430–2438. [CrossRef]
20. Wang, Y.H.; Nemati, R.; Anstadt, E.; Liu, Y.; Son, Y.; Zhu, Q.; Yao, X.; Clark, R.B.; Rowe, D.W.; Nichols, F.C.
Serine dipeptide lipids of Porphyromonas gingivalis inhibit osteoblast differentiation: Relationship to Toll-like
receptor 2. Bone 2015, 81, 654–661. [CrossRef]
21. Olsen, I.; Nichols, F.C. Are Sphingolipids and serine dipeptide lipids underestimated virulence factors of
Porphyromonas gingivalis? Infect. Immun. 2018, 86, e00035-18. [CrossRef]
22. Nemati, R.; Dietz, C.; Anstadt, E.J.; Cervantes, J.; Liu, Y.; Dewhirst, F.E.; Clark, R.B.; Finegold, S.; Gallagher, J.J.;
Smith, M.B.; et al. Deposition and hydrolysis of serine dipeptide lipids of Bacteroidetes bacteria in human
arteries: Relationship to atherosclerosis. J. Lipid Res. 2017, 58, 1999–2007. [CrossRef]
23. Nemati, R.; Dietz, C.; Anstadt, E.; Clark, R.; Smith, M.; Nichols, F.; Yao, X. Simultaneous determination of
absolute configuration and quantity of lipopeptides using chiral liquid chromatography/mass spectrometry
and diastereomeric internal standards. Anal. Chem. 2017, 89, 3583–3589. [CrossRef]
Molecules 2019, 24, 3991 15 of 15
24. Kristoffersen, V.; Rämä, T.; Isaksson, J.; Andersen, J.H.; Gerwick, W.H.; Hansen, E. Characterization of
Rhamnolipids produced by an arctic marine bacterium from the Pseudomonas fluorescence group. Mar. Drugs
2018, 16, 163. [CrossRef]
25. Sasaki, D.T.; Dumas, S.E.; Engleman, E.G. Discrimination of viable and non-viable cells using propidium
iodide in two color immunofluorescence. Cytometry 1987, 8, 413–420. [CrossRef]
26. Pietkiewicz, S.; Schmidt, J.H.; Lavrik, I.N. Quantification of apoptosis and necroptosis at the single cell level
by a combination of imaging flow cytometry with classical annexin V/propidium iodide staining. J. Immun.
Methods 2015, 423, 99–103. [CrossRef]
27. Mascotti, K.; McCullough, J.; Burger, S.R. HPC viability measurement: Trypan blue versus acridine orange
and propidium iodide. Transfusion 2000, 40, 693–696. [CrossRef]
28. Hamley, I.W. Lipopeptides: From self-assembly to bioactivity. Chem. Commun. 2015, 51, 8574–8583.
[CrossRef]
29. Raaijmakers, J.M.; De Bruijn, I.; Nybroe, O.; Ongena, M. Natural functions of lipopeptides from Bacillus and
Pseudomonas: More than surfactants and antibiotics. FEMS Microbiol. Rev. 2010, 34, 1037–1062. [CrossRef]
30. Seydlová, G.; Svobodová, J. Review of surfactin chemical properties and the potential biomedical applications.
Cent. Eur. J. Med. 2008, 3, 123–133. [CrossRef]
31. Baltz, R.H. Daptomycin: Mechanisms of action and resistance, and biosynthetic engineering. Curr. Opin.
Chem. Biol. 2009, 13, 144–151. [CrossRef] [PubMed]
32. Mor, A.; Gurwitz, D. Peptide-based antibiotics: A potential answer to raging antimicrobial resistance. Drug
Dev. Res. 2000, 50, 440–447. [CrossRef]
33. Humphries, R.M.; Pollett, S.; Sakoulas, G. A current perspective on Daptomycin for the clinical microbiologist.
Clin. Microbiol. Rev. 2013, 26, 759–780. [CrossRef] [PubMed]
34. Debono, M.; Abbott, B.J.; Molloy, R.M.; Fukuda, D.S.; Hunt, A.H.; Daupert, V.M.; Counter, F.T.; Ott, J.L.;
Carrell, C.B.; Howard, L.C.; et al. Enzymatic and chemical modifications of lipopeptide antibiotic A21978C:
The synthesis and evaluation of Daptomycin (LY146032). J. Antibiot. 1988, 41, 1093–1105. [CrossRef]
[PubMed]
35. Peypoux, F.; Bonmatin, J.M.; Wallach, J. Recent trends in the biochemistry of surfactin. Appl. Microbiol.
Biotech. 1999, 51, 553–563. [CrossRef] [PubMed]
36. Tareq, F.S.; Lee, M.A.; Lee, H.-S.; Lee, J.-S.; Lee, Y.-J.; Shin, H.J. Gageostatins A-C, antimicrobial linear
lipopeptides from a marine Bacillus Subtilis. Mar. Drugs 2014, 12, 871–885. [CrossRef] [PubMed]
37. Makovitzki, A.; Avrahami, D.; Shai, Y. Ultrashort antibacterial and antifungal lipopeptides. Proc. Natl. Acad.
Sci. USA 2006, 103, 15997–16002. [CrossRef]
38. Chrzanowski, Ł.; Ławniczak, Ł.; Czaczyk, K. Why do microorganisms produce rhamnolipids? World J.
Microbiol. Biotechnol. 2012, 28, 401–419. [CrossRef]
39. Abdel-Mawgoud, A.; Lépine, F.; Déziel, E. Rhamnolipids: Diversity of structures, microbial origins and roles.
Appl. Microbiol. Biotechnol. 2010, 86, 1323–1336. [CrossRef]
Sample Availability: Samples of the compound 1 are available from the authors.
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
